Zoetis Reports Second Quarter 2016 Results
-
For Second Quarter 2016, Zoetis Reports Revenue of $1.2 Billion,
Growing 3%, and Net Income of $224 Million, or $0.45 per Diluted
Share, on a Reported Basis -
Zoetis Reports Adjusted Net Income of $246 Million, or Adjusted
Diluted EPS of $0.49, for Second Quarter 2016 -
Zoetis Delivers 6% Operational Growth in Revenue and 22%
Operational Growth in Adjusted Net Income, Excluding Foreign Exchange,
for Second Quarter 2016 -
Zoetis Increases Full Year 2016 Revenue Guidance to $4.800 – $4.900
Billion and Diluted EPS to $1.52 – $1.63 on a Reported Basis, or $1.86
– $1.93 on an Adjusted Basis
FLORHAM PARK, N.J.–(BUSINESS WIRE)–$ZTS #animalhealth—Zoetis
Inc. (NYSE:ZTS) today reported its financial results for the second
quarter of 2016 and increased its revenue and adjusted net income
guidance for full year 2016.
The company reported revenue of $1.2 billion for the second quarter of
2016, an increase of 3% compared with the second quarter of 2015. Net
income for the second quarter of 2016 was $224 million, or $0.45 per
diluted share, compared with a net loss of $37 million for the second
quarter of 2015, on a reported basis.
Adjusted net income1 for the second quarter of 2016 was $246
million, or $0.49 per diluted share, an increase of 14%. Adjusted net
income for the second quarter of 2016 excludes the net impact of $22
million for purchase accounting adjustments, acquisition-related costs
and certain significant items.
On an operational2 basis, revenue for the second quarter of
2016 increased 6%, excluding the impact of foreign currency. Adjusted
net income for the second quarter of 2016 increased 22% operationally,
excluding the impact of foreign currency.
EXECUTIVE COMMENTARY
“We have continued our positive momentum through the first half of the
year based on the strengths of our diverse portfolio and dedicated
Zoetis colleagues,” said Zoetis Chief Executive Officer Juan Ramón
Alaix. “In the second quarter, we delivered 6% operational revenue
growth, driven by strong sales of our companion animal products and the
positive performance of the U.S. cattle business. We also grew adjusted
net income significantly faster than revenue – 22% operationally – as
cost controls and efficiency improvements are progressing.
“We also continue to reap the benefits of a productive, world-class R&D
organization focused on new discoveries like APOQUEL and SIMPARICA, as
well as lifecycle innovations across our approximately 300 product
lines,” said Alaix. “Our investments in internal R&D and external
business development opportunities have us well-positioned as the world
leader in animal health today and into the future.”
“We’ve made a number of operational efficiency changes over the last
year that have and will negatively impact our reported revenue growth in
2016. However, our go-forward product portfolio and revised
international footprint delivered strong revenue growth in the second
quarter and over the first half of 2016,” said Paul Herendeen, Executive
Vice President and Chief Financial Officer of Zoetis. “These efficiency
improvements and our execution of new product launches have us on track
to achieve our updated financial guidance for 2016 and improve our
profitability for the long term.”
QUARTERLY HIGHLIGHTS
Zoetis organizes and manages its business across two regional operating
segments: the United States (U.S.) and International. Within these
segments, the company delivers a diverse portfolio of products for
livestock and companion animals tailored to local trends and customer
needs. In the second quarter of 2016:
-
Revenue in the U.S. segment was $594 million, an increase of
10% compared with the second quarter of 2015. Sales of companion
animal products grew 17%, due primarily to increased sales of APOQUEL®
and several new product launches, including SIMPARICA™.
Livestock revenue grew 2%, driven by increased sales of our cattle
products as a result of improving market conditions and expanding herd
sizes. Livestock revenue growth was partially offset by product
rationalizations as part of the company’s operational efficiency
initiative that impacted poultry and swine; swine also
declined due to increased competition. -
Revenue in the International segment was $602 million, a
decrease of 3% on a reported basis and an increase of 2% operationally
compared with the second quarter of 2015. Sales of companion animal
products grew 2% on a reported basis and 6% operationally, driven
primarily by sales of APOQUEL across a variety of markets and growth
in China, primarily from the company’s vaccines portfolio. Growth in
companion animal products was partially offset by product
rationalizations as a result of the company’s operational efficiency
initiative and business reductions in Venezuela. Sales of livestock
products decreased 5% on a reported basis and grew 1% operationally,
primarily from the addition of revenue from PHARMAQ and growth in
China due to favorable market conditions in the swine market. Poultry
and cattle products declined primarily due to business reductions in
Venezuela and India, in addition to product rationalizations as a
result of the company’s operational efficiency initiative.
Zoetis continues to drive demand and strengthen its diverse portfolio of
products through lifecycle innovations, strong customer relationships
and access to new markets and technologies. The company is focused on
improving the performance and delivery of its current product lines;
expanding product indications across species; pursuing approvals in new
geographies; and developing and marketing innovative medicines,
treatments and solutions for emerging diseases and unmet customer needs.
Some recent highlights include:
-
On the companion animal side, Zoetis strengthened its vaccine
portfolio, expanding its VERSICAN® Plus
and VANGUARD® vaccine franchises with new
approvals in Europe and Canada.-
VERSICAN Plus, a combination vaccine for dogs containing
nine vaccine antigens that help protect against ten canine
diseases, was first approved in the European Union in 2014, and
this quarter received additional approvals in the United Kingdom,
Denmark, Sweden and the Netherlands for smaller combinations of
the vaccine. These smaller combinations provide veterinarians with
further flexibility to tailor their vaccination programs to meet
the needs of their patients. Additionally, VERSICAN Plus Rabies
gained approval for a new claim – three years duration of immunity
– in the European Union. -
VANGUARD® B Oral and VANGUARD®
crLyme vaccines were approved in Canada. These vaccines, which
were granted United States Department of Agriculture (USDA)
licensure in December 2015, help protect against Bordetella
bronchiseptica, a common pathogen in canine infectious
respiratory disease, and Borrelia burgdorferi, the
causative agent of Lyme disease in dogs.
FINANCIAL GUIDANCE
Zoetis’ guidance for the full year 2016 has been increased to reflect
the company’s strong performance in the first half of the year, the
continued strength of its business model, and its confidence in the
outlook for the remainder of the year. The company’s guidance for the
full year 2016 is the following:- Revenue of between $4.800 billion to $4.900 billion
-
Reported diluted EPS for the full year of between $1.52 to $1.63 per
share - Adjusted diluted EPS for the full year between $1.86 to $1.93 per share
Additional guidance on other items such as expenses and tax rate is
included in the financial tables and will be discussed on the company’s
conference call this morning. This guidance reflects foreign exchange
rates as of late July.WEBCAST & CONFERENCE CALL DETAILS
Zoetis will host a webcast and conference call at 8:30 a.m. (EDT) today,
during which company executives will review second quarter 2016 results,
discuss financial guidance and respond to questions from financial
analysts. Investors and the public may access the live webcast by
visiting the Zoetis website at http://investor.zoetis.com/events-presentations.
A replay of the webcast will be archived and made available on Aug. 3,
2016.About Zoetis
Zoetis
(zô-EH-tis) is the leading animal health company, dedicated to
supporting its customers and their businesses. Building on more than 60
years of experience in animal health, Zoetis discovers, develops,
manufactures and markets veterinary vaccines and medicines, complemented
by diagnostic products and genetic tests and supported by a range of
services. Zoetis serves veterinarians, livestock producers and people
who raise and care for farm and companion animals with sales of its
products in more than 100 countries. In 2015, the company generated
annual revenue of $4.8 billion with approximately 9,000 employees. For
more information, visit www.zoetis.com.1 Adjusted net income and its components and
adjusted diluted earnings per share (non-GAAP financial measures) are
defined as reported net income attributable to Zoetis and reported
diluted earnings per share, excluding purchase accounting adjustments,
acquisition-related costs and certain significant items.2 Operational revenue growth (a non-GAAP financial
measure) is defined as revenue growth excluding the impact of foreign
exchange.DISCLOSURE NOTICES
Forward-Looking Statements: This
press release contains forward-looking statements, which reflect the
current views of Zoetis with respect to business plans or prospects,
future operating or financial performance, future guidance, future
operating models, expectations regarding products, future use of cash
and dividend payments, tax rate and tax regimes, changes in the tax
regimes and laws in other jurisdictions, and other future events. These
statements are not guarantees of future performance or actions.
Forward-looking statements are subject to risks and uncertainties. If
one or more of these risks or uncertainties materialize, or if
management’s underlying assumptions prove to be incorrect, actual
results may differ materially from those contemplated by a
forward-looking statement. Forward-looking statements speak only as of
the date on which they are made. Zoetis expressly disclaims any
obligation to update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise. A further list
and description of risks, uncertainties and other matters can be found
in our Annual Report on Form 10-K for the fiscal year ended December 31,
2015, including in the sections thereof captioned “Forward-Looking
Information and Factors That May Affect Future Results” and “Item 1A.
Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current
Reports on Form 8-K. These filings and subsequent filings are available
online at www.sec.gov, www.zoetis.com,
or on request from Zoetis.Use of Non-GAAP Financial Measures:
We use non-GAAP financial measures, such as adjusted net income,
adjusted diluted earnings per share and operational results (which
exclude the impact of foreign exchange), to assess and analyze our
results and trends and to make financial and operational decisions. We
believe these non-GAAP financial measures are also useful to investors
because they provide greater transparency regarding our operating
performance. The non-GAAP financial measures included in this press
release should not be considered alternatives to measurements required
by GAAP, such as net income, operating income, and earnings per share,
and should not be considered measures of liquidity. These non-GAAP
financial measures are unlikely to be comparable with non-GAAP
information provided by other companies. Reconciliation of non-GAAP
financial measures and GAAP financial measures are included in the
tables accompanying this press release and are posted on our website at www.zoetis.com.Internet Posting of Information:
We routinely post information that may be important to investors in the
‘Investors’ section of our website at www.zoetis.com,
on our Facebook page at http://www.facebook.com/zoetis
and on Twitter @zoetis. We encourage investors and potential investors
to consult our website regularly and to follow us on Facebook and
Twitter for important information about us.ZOETIS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(a)
(UNAUDITED)
(millions
of dollars, except per share data)Second Quarter Six Months 2016 2015 % Change 2016 2015 % Change Revenue $ 1,208 $ 1,175 3 $ 2,370 $ 2,277 4 Costs and expenses: Cost of sales(b) 399 427 (7) 788 821 (4) Selling, general and administrative expenses(b) 343 379 (9) 658 733 (10) Research and development expenses(b) 88 84 5 178 164 9 Amortization of intangible assets(c) 22 15 47 43 30 43 Restructuring (benefits)/charges and certain acquisition-related
costs(21 ) 266 * (19 ) 267 * Interest expense 41 29 41 84 57 47 Other (income)/deductions–net 4 2 100 (26 ) 2 * Income/(Loss) before provision for taxes on income 332 (27 ) * 664 203 * Provision for taxes on income 108 9 * 236 74 * Net income/(loss) before allocation to noncontrolling interests 224 (36 ) * 428 129 * Less: Net income attributable to noncontrolling interests — 1 (100) — 1 (100) Net income/(loss) attributable to Zoetis $ 224 $ (37 ) * $ 428 $ 128 * Earnings/(Loss) per share—basic $ 0.45 $ (0.07 ) * $ 0.86 $ 0.26 * Earnings/(Loss) per share—diluted $ 0.45 $ (0.07 ) * $ 0.86 $ 0.25 * Weighted-average shares used to calculate earnings per share Basic 496.3 500.2 496.9 500.7 Diluted 498.8 500.2 499.2 502.9 * Calculation not meaningful. (a) The condensed consolidated statements of income present the three
and six months ended July 3, 2016, and June 28, 2015. Subsidiaries
operating outside the United States are included for the three and
six months ended May 29, 2016 and May 24, 2015.(b) Exclusive of amortization of intangible assets, except as discussed
in footnote (c) below.(c) Amortization expense related to finite-lived acquired intangible
assets that contribute to our ability to sell, manufacture,
research, market and distribute products, compounds and
intellectual property is included in Amortization of intangible
assets as these intangible assets benefit multiple business
functions. Amortization expense related to finite-lived acquired
intangible assets that are associated with a single function is
included in Cost of sales, Selling, general and administrative
expenses or Research and development expenses, as
appropriate.Certain amounts and percentages may reflect rounding adjustments. ZOETIS INC.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP
ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions
of dollars, except per share data)Quarter ended July 3, 2016 GAAP
Reported(a)Purchase
Accounting
AdjustmentsAcquisition
– Related
Costs(1)Certain
Significant
Items(2)Non-GAAP
Adjusted(b)Revenue $ 1,208 $ — $ — $ — $ 1,208 Cost of sales(c) 399 (8 ) — (3 ) 388 Gross profit 809 8 — 3 820 Selling, general and administrative expenses(c) 343 (2 ) — (10 ) 331 Research and development expenses(c) 88 — — — 88 Amortization of intangible assets(d) 22 (18 ) — — 4 Restructuring (benefits)/charges and certain acquisition-related
costs(21 ) — (2 ) 23 — Interest expense 41 — — — 41 Other (income)/deductions–net 4 — — (6 ) (2 ) Income before provision for taxes on income 332 28 2 (4 ) 358 Provision for taxes on income 108 10 1 (7 ) 112 Net income attributable to Zoetis 224 18 1 3 246 Earnings per common share attributable to Zoetis–diluted(e) 0.45 0.04 — — 0.49 Quarter ended June 28, 2015 GAAP
Reported(a)Purchase
AccountingAdjustments
Acquisition
– Related
Costs(1)Certain
Significant
Items(2)Non-GAAP
Adjusted(b)Revenue $ 1,175 $ — $ — $ — $ 1,175 Cost of sales(c) 427 (3 ) — (18 ) 406 Gross profit 748 3 — 18 769 Selling, general and administrative expenses(c) 379 — — (36 ) 343 Research and development expenses(c) 84 (1 ) — — 83 Amortization of intangible assets(d) 15 (11 ) — — 4 Restructuring charges and certain acquisition-related costs 266 — (3 ) (263 ) — Interest expense 29 — — — 29 Other (income)/deductions–net 2 — (1 ) (2 ) (1 ) Income before provision for taxes on income (27 ) 15 4 319 311 Provision for taxes on income 9 3 — 82 94 Income/(Loss) from continuing operations (36 ) 12 4 237 217 Net income attributable to noncontrolling interests 1 — — — 1 Net income/(loss) attributable to Zoetis (37 ) 12 4 237 216 Earnings/(Loss) per common share attributable to Zoetis–diluted(e) (0.07 ) 0.02 0.01 0.47 0.43 ZOETIS INC.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP
ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions
of dollars, except per share data)Six months ended July 3, 2016 GAAP
Reported(a)Purchase
Accounting
AdjustmentsAcquisition –
Related
Costs(1)Certain
Significant
Items(2)Non-GAAP
Adjusted(b)Revenue $ 2,370 $ — $ — $ — $ 2,370 Cost of sales(c) 788 (15 ) — (7 ) 766 Gross profit 1,582 15 — 7 1,604 Selling, general and administrative expenses(c) 658 (3 ) — (24 ) 631 Research and development expenses(c) 178 (1 ) — — 177 Amortization of intangible assets(d) 43 (35 ) — — 8 Restructuring (benefits)/charges and certain acquisition-related
costs(19 ) — (2 ) 21 — Interest expense 84 — — — 84 Other (income)/deductions–net (26 ) — (1 ) 27 — Income before provision for taxes on income 664 54 3 (17 ) 704 Provision for taxes on income 236 27 (1 ) (43 ) 219 Net income attributable to Zoetis 428 27 4 26 485 Earnings per common share attributable to Zoetis–diluted(e) 0.86 0.05 0.01 0.05 0.97 Six months ended June 28, 2015 GAAP
Reported(a)Purchase
Accounting
AdjustmentsAcquisition –
Related
Costs(1)Certain
Significant
Items(2)Non-GAAP
Adjusted(b)Revenue $ 2,277 $ — $ — $ — $ 2,277 Cost of sales(c) 821 (5 ) — (25 ) 791 Gross profit 1,456 5 — 25 1,486 Selling, general and administrative expenses(c) 733 — — (70 ) 663 Research and development expenses(c) 164 (1 ) — — 163 Amortization of intangible assets(d) 30 (22 ) — — 8 Restructuring charges and certain acquisition-related costs 267 — (4 ) (263 ) — Interest expense 57 — — — 57 Other (income)/deductions–net 2 — (1 ) (2 ) (1 ) Income before provision for taxes on income 203 28 5 360 596 Provision for taxes on income 74 10 (2 ) 90 172 Income from continuing operations 129 18 7 270 424 Net income attributable to noncontrolling interests 1 — — — 1 Net income attributable to Zoetis 128 18 7 270 423 Earnings per common share attributable to Zoetis–diluted(e) 0.25 0.04 0.01 0.54 0.84 (a) The condensed consolidated statements of income present the three
and six months ended July 3, 2016, and June 28, 2015. Subsidiaries
operating outside the United States are included for the three and
six months ended May 29, 2016 and May 24, 2015.(b) Non-GAAP adjusted net income and its components and non-GAAP
adjusted diluted EPS are not, and should not be viewed as,
substitutes for U.S. GAAP net income and its components and diluted
EPS. Despite the importance of these measures to management in goal
setting and performance measurement, non-GAAP adjusted net income
and its components and non-GAAP adjusted diluted EPS are non-GAAP
financial measures that have no standardized meaning prescribed by
U.S. GAAP and, therefore, have limits in their usefulness to
investors. Because of the non-standardized definitions, non-GAAP
adjusted net income and its components and non-GAAP adjusted diluted
EPS (unlike U.S. GAAP net income and its components and diluted EPS)
may not be comparable to the calculation of similar measures of
other companies. Non-GAAP adjusted net income and its components,
and non-GAAP adjusted diluted EPS are presented solely to permit
investors to more fully understand how management assesses
performance.(c) Exclusive of amortization of intangible assets, except as discussed
in footnote (d) below.(d) Amortization expense related to finite-lived acquired intangible
assets that contribute to our ability to sell, manufacture,
research, market and distribute products, compounds and
intellectual property is included in Amortization of intangible
assets as these intangible assets benefit multiple business
functions. Amortization expense related to finite-lived acquired
intangible assets that are associated with a single function is
included in Cost of sales, Selling, general and administrative
expenses or Research and development expenses, as
appropriate.(e) EPS amounts may not add due to rounding. See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted
Information for notes (1) and (2).Certain amounts may reflect rounding adjustments. ZOETIS INC.
NOTES TO RECONCILIATION OF GAAP REPORTED TO
NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions
of dollars)(1) Acquisition-related costs include the following:
Second Quarter Six Months 2016 2015 2016 2015 Integration costs(a) $ 2 $ 3 $ 2 $ 4 Other(b) — 1 1 1 Total acquisition-related costs—pre-tax 2 4 3 5 Income taxes(c) 1 — (1 ) (2 ) Total acquisition-related costs—net of tax $ 1 $ 4 $ 4 $ 7 (a) Integration costs represent external, incremental costs directly
related to integrating acquired businesses and primarily include
expenditures for consulting and the integration of systems and
processes. Included in Restructuring (benefits)/charges and
certain acquisition-related costs.(b) Included in Other (income)/deductions—net.
(c) Included in Provision for taxes on income. Income taxes
include the tax effect of the associated pre-tax amounts,
calculated by determining the jurisdictional location of the
pre-tax amounts and applying that jurisdiction’s applicable tax
rate, as well as a tax charge related to the acquisition of
certain assets of Abbott Animal Health.Certain amounts may reflect rounding adjustments. (2) Certain significant items include the following:
Second Quarter Six Months 2016 2015 2016 2015 Operational efficiency initiative(a) $ (17 ) $ 263 $ (45 ) $ 273 Supply network strategy(b) 8 15 11 20 Other restructuring charges and cost-reduction/productivity
initiatives(c)(1 ) — (1 ) — Stand-up costs(d) 5 39 17 62 Other(e) 1 2 1 5 Total certain significant items—pre-tax (4 ) 319 (17 ) 360 Income taxes(f) (7 ) 82 (43 ) 90 Total certain significant items—net of tax $ 3 $ 237 $ 26 $ 270 (a) For the three months ended July 3, 2016, represents a reduction in
employee termination accruals ($30 million benefit) and an
increase in exit costs ($2 million), included in Restructuring
(benefits)/charges and certain acquisition-related costs,
accelerated depreciation of $1 million and consulting fees of $4
million, included in Selling, general and administrative
expenses, and a $6 million net loss related to divestitures,
included in Other (income)/deductions—net. For the six
months ended July 3, 2016, represents a reduction in employee
termination accruals ($29 million benefit) and an increase in exit
costs ($3 million), included in Restructuring
(benefits)/charges and certain acquisition-related costs,
accelerated depreciation of $1 million and consulting fees of $7
million, included in Selling, general and administrative
expenses, and a $27 million net gain related to divestitures,
included in Other (income)/deductions—net. The three and
six months ended June 28, 2015, represents restructuring charges
of $253 million related to employee termination costs ($228
million) and asset impairments ($25 million), included in Restructuring
(benefits)/charges and certain acquisition-related costs.
Additionally, the three and six months ended June 28, 2015 include
consulting fees of $10 million and $20 million, respectively,
included in Selling, general and administrative expenses.(b) For the three and six months ended July 3, 2016, represents
restructuring charges of $6 million related to employee
termination costs, included in Restructuring (benefits)/charges
and certain acquisition-related costs, and accelerated
depreciation charges of $1 million and $2 million, respectively,
and consulting fees of $1 million and $3 million, respectively,
included in Cost of sales. For the three and six months
ended June 28, 2015, represents restructuring charges of $10
million related to employee termination costs ($9 million) and
asset impairments ($1 million), included in Restructuring
(benefits)/charges and certain acquisition-related costs.
Additionally, the three and six months ended June 28, 2015,
include consulting fees of $5 million and $10 million,
respectively, included in Cost of sales.(c) Included in Restructuring (benefits)/charges and certain
acquisition-related costs.(d) Represents certain nonrecurring costs related to becoming an
independent public company, such as the creation of standalone
systems and infrastructure, site separation, new branding
(including changes to the manufacturing process for required new
packaging), and certain legal registration and patent assignment
costs. For the three and six months ended July 3, 2016, included
in Cost of sales ($1 million and $2 million, respectively)
and Selling, general and administrative expenses ($4
million and $15 million, respectively). For the three and six
months ended June 28, 2015, included in Cost of sales ($12
million and $14 million, respectively) and Selling, general and
administrative expenses ($27 million and $48 million,
respectively).(e) The three and six months ended July 3, 2016, represents costs
associated with changes to our operating model in Selling,
general and administrative expenses. The three and six months
ended June 28, 2015, includes an impairment of IPR&D assets
related to a discontinued canine oncology project ($2 million) in Other
(income)/deductions—net. The six months ended June 28, 2015,
also includes charges due to unusual investor-related activities
($3 million) in Selling, general and administrative expenses.(f) Included in Provision for taxes on income. Income taxes
include the tax effect of the associated pre-tax amounts,
calculated by determining the jurisdictional location of the
pre-tax amounts and applying that jurisdiction’s applicable tax
rate. The three and six months ended July 3, 2016, also includes a
net tax charge of approximately $3 million and $38 million,
respectively, related to the impact of the European Commission’s
negative decision on the excess profits rulings in Belgium. These
net charges relate to the Belgium government’s recovery of prior
tax benefits for the periods 2013 through 2015 offset by the
revaluation of the company’s deferred tax assets and liabilities
using the rates expected to be in place at the time of the
reversal. These net charges do not include any benefits associated
with a successful appeal of the decision.Certain amounts may reflect rounding adjustments. Contacts
Zoetis Inc.
Media:
Bill Price,
1-973-443-2742 (o)
william.price@zoetis.com
or
Elinore
White, 1-973-443-2835 (o)
elinore.y.white@zoetis.com
or
Investors:
Steve
Frank, 1-973-822-7141 (o)
steve.frank@zoetis.com -
VERSICAN Plus, a combination vaccine for dogs containing
